E-mail a Wiley Online Library Link

Yesid Alvarado, Hagop M. Kantarjian, Rajyalakshmi Luthra, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia-Manero, Marina Konopleva, Zeev Estrov, Michael Andreeff and Jorge E. Cortes Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations Cancer 120

Version of Record online: 15 APR 2014 | DOI: 10.1002/cncr.28705

Secondary FLT3-tyrosine kinase domain mutations can arise after treatment with FLT3 inhibitors in patients with FLT3-internal tandem duplication–mutated acute myeloid leukemia. D835/I836 mutations were observed in at least 20% of patients after treatment, and are associated with resistance and poor prognosis.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field